Background
Insys Therapeutics marketed Subsys, a fentanyl spray approved for breakthrough cancer pain, through a speaker program that purportedly paid physicians to educate other medical professionals. According to the trial evidence, the program instead rewarded high-prescribing physicians with honoraria in exchange for writing more Subsys prescriptions, while sham or poorly attended events and inaccurate sign-in sheets gave the payments an appearance of legitimacy.
Dr. Steven Chun, a pain-medicine specialist and Medicare provider, received $278,900 as an Insys speaker between 2012 and 2015. Daniel Tondre, an Insys sales representative whose territory included Chun’s practice, arranged most of Chun’s approximately 100 programs. A jury convicted both defendants of conspiring to violate the federal Anti-Kickback Statute. It also convicted Chun of five substantive kickback-receipt offenses and Tondre of five kickback-payment offenses and two identification-fraud offenses. Chun received a 42-month prison sentence, and Tondre received 48 months.
The Court’s Holding
The Eleventh Circuit affirmed the convictions. It held that overwhelming evidence allowed a rational jury to find that Chun, Tondre, and Insys personnel agreed to exchange speaker payments for Subsys prescriptions. Adopting the Fifth Circuit’s interpretation of the Anti-Kickback Statute’s federal-healthcare element, the court held that the government need only show the defendant knowingly agreed to accept remuneration for referrals or orders involving patients who could be federally insured. Evidence that Chun participated in Medicare and treated Medicare patients satisfied that requirement. The evidence also supported a finding that Chun and Tondre acted willfully, including testimony about sham programs, forged sign-in sheets, increasing prescriptions, and the payments-for-prescriptions arrangement. Tondre waived the statute’s employee safe-harbor affirmative defense by failing to raise it at trial.
The court also held that the district court did not abuse its discretion in responding to two jury questions by identifying admitted exhibits that might contain requested pricing and text-message information. The responses neither resolved disputed facts nor improperly endorsed the government’s characterization of the evidence. Finally, the Eleventh Circuit declined to resolve whether the sentencing court should have used Insys’s net profit rather than gross Medicare payments to calculate the improper benefit. Any potential Guidelines error was harmless because the district court expressly stated that it would impose the same sentences under the defendants’ preferred calculations, and the resulting sentences were substantively reasonable.
Key Takeaways
- The Anti-Kickback Statute’s federal-healthcare element is satisfied when a defendant knowingly agrees to accept remuneration involving patients who could be federally insured; the government need not trace every transaction to an actual federal payment.
- A sham speaker program may support kickback convictions when evidence shows that honoraria were exchanged for prescriptions, even if the physician did not personally forge every document used to conceal the arrangement.
- A district court may direct deliberating jurors to admitted exhibits responsive to their questions so long as it does not resolve factual disputes, misstate the law, or endorse particular evidence.
- A disputed Guidelines calculation is harmless when the sentencing judge would impose the same substantively reasonable sentence under the defendant’s preferred calculation.
Why It Matters
The published decision supplies Eleventh Circuit precedent on what connects a kickback arrangement to a federal healthcare program. By requiring only the possibility that referred patients could be federally insured, the ruling rejects a transaction-by-transaction tracing requirement and gives prosecutors a comparatively straightforward way to establish the statutory nexus in mixed-payor medical practices.
The opinion also underscores the criminal exposure created by pharmaceutical speaker programs whose compensation tracks prescribing volume rather than genuine educational services. Its harmless-error analysis further shows the importance of a sentencing court clearly stating whether it would impose the same sentence under an alternative Guidelines calculation.